Ads are not configured at this scope yet
Full access
Psychopharmacology
Published Online: 19 February 2016

Industry Briefs

Vabren WattsAuthors Info & Affiliations
Volume 2, Number 3
https://doi.org/10.1176/appi.pn.2016.PP2b5
PDF/EPUB

Alkermes Begins Phase 3 Trial of Antipsychotic

Last week, Alkermes announced the initiation of a second phase 3 trial for the once-daily oral atypical antipsychotic medication ALKS-3831 (combined tablet of samidorphan and olanzapine) intended for the treatment of schizophrenia.
The trial, known as ENLIGHTEN-2, is a multicenter, randomized, double-blind phase 3 study that is comparing weight gain, safety, and tolerability of ALKS-3831 with that of olanzapine monotherapy in approximately 540 patients with schizophrenia over six months.
All participants in the double-blind portion of the study will be eligible to continue in an open-label safety study of ALKS-3831 for an additional 12 months, which will assess the safety and long-term tolerability of the medication.
The results of phase 2 trials, released last year, showed ALKS-3831 to be as effective at reducing symptoms of schizophrenia as olanzapine with less weight gain than that of olanzapine monotherapy over three months (Psychiatric News, May 1, 2015).

FDA Updates Iloperidone Label on Adverse Events

Last month, the Food and Drug Administration updated the label of Fanapt (iloperidone) tablets after postmarketing reports indicated patients taking the medication may be at an increased risk for hypersensitivity reactions (including anaphylaxis; angioedema; throat tightness; oropharyngeal swelling; swelling of the face, lips, mouth, and tongue; urticaria; rash; and pruritus). ■

Information & Authors

Information

Published In

Go to Psychopharmacology
Volume 2 • Number 3 • February 19, 2016
Pages: 1

History

Published online: 19 February 2016
Published in print: February 19, 2016

Keywords

  1. ALKS 3831
  2. Antipsychotic
  3. Schizophrenia
  4. iloperidone

Authors

Details

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard
Tips for downloading citations

There are no citations for this item

View Options

View options

PDF/ePub

View PDF/ePub

Get Access

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share

×

As described within the American Psychiatric Association (APA)'s Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences. Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.